KALV

KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV

Kalvista Pharmaceuticals stock rating cut to neutral by H.C. Wainwright on merger deal

Stock Market Today, April 29: KalVista Pharmaceuticals Surges on Chiesi Group Acquisition Announcement

KalVista Scores $1.9 Billion Takeover Deal; Why A Key Rival Jumped Too

KalVista: 'Strong Buy' As Acquired By Chiesi And Positive KONFIDENT-KID Outcome (KALV)

KalVista climbs on $1.9B buyout deal with Chiesi (KALV:NASDAQ)

Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio

KalVista CCO Nicole Sweeny sells $37,642 in company stock

KalVista chief medical officer sells $54,300 in stock

KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference

KalVista Pharmaceuticals: Ekterly's Launch Momentum Keeps The Bull Case Alive (KALV)